Human Microbiome-based Drugs and Diagnostics expected to reach $9.9 billion by 2024

News provided by

Jun 05, 2017, 12:45 ET

LONDON, June 5, 2017 /PRNewswire/ -- Highlights

· The global market for human microbiome-based drugs and diagnostics should reach a market size of nearly $9.9 billion by 2024.

· The human microbiome-based drugs constitute 95% of this market and should reach $9.3 billion in sales by 2024.

· The size of the microbiome diagnostics market is expected to remain modest at $543.8 million in 2024.

· The objective of this study is to review the development of human microbiome-based drugs and diagnostics and assess their market potential for the U.S., Europe, Japan, China and rest of world geographies.

· We are particularly interested in characterizing the market for microbiome-based drugs for various diseases that are linked with the dysregulation in human microbiome.

· A focus of this report is to describe the microbial associations of various diseases, present a comprehensive profile of the microbiome-based drugs in the clinical development and finally provide the projections on the market size of microbiome-based drugs in various disease areas for the time period of 2018 to 2024.

· The human body is a home to over 100 trillion microbes and over 2 million microbial genes.

· Microbiome is a term that represents all of the microbial genes.

· Microbes residing inside and on the human bodies play a significant role in the body's physiological functions—some beneficial and others harmful.

· Our knowledge and understanding of the role that microbes play in various diseases has grown exponentially since the completion of Human Microbiome Project in 2012.

· This field has seen a tremendous explosion in research and development activities in microbiome-based drugs and diagnostics.

· The human microbiome-based drugs and diagnostics pipeline is strong with over 25 companies active in this space and over 50 programs in clinical/preclinical development.

• The global market for human microbiome-based drugs and diagnostics should reach a market size of nearly $9.9 billion by 2024.
• The human microbiome-based drugs constitute 95% of this market and should reach $9.3 billion in sales by 2024.

• The size of the microbiome diagnostics market is expected to remain modest at $543.8 million in 2024.

Introduction

Study Goals and Objectives
The objective of this study is to review the development of human microbiome-based drugs and diagnostics and assess their market potential for the U.S., Europe, Japan, China and rest of world geographies. We are particularly interested in characterizing the market for microbiome-based drugs for various diseases that are linked with the dysregulation in human microbiome. A focus of this report is to describe the microbial associations of various diseases, present a
comprehensive profile of the microbiome-based drugs in the clinical development and finally provide the projections on the market size of microbiome-based drugs in various disease areas for the time period of 2018 to 2024.

Reasons for Doing This Study
The human body is a home to over 100 trillion microbes and over 2 million microbial genes. Microbiome is a term that represents all of the microbial genes. So, the human microbiome is, in a sense, our second genome. Microbes residing inside and on the human bodies play a significant role in the body's physiological functions—some beneficial and others harmful. Our knowledge and understanding of the role that microbes play in various diseases has grown exponentially since the completion of Human Microbiome Project in 2012. This field has seen a tremendous explosion in research and development activities in microbiome-based drugs and diagnostics. The field has also attracted substantial public and private sector investments. Collectively, these developments have created a new sector—human microbiome-based drugs and diagnostics.

Enterprising new start-ups are teaming up with top academic institutions, and leading pharmaceutical companies to tackle diseases ranging from gastrointestinal disorders, cancers, metabolic disorders to rare diseases. Thus, it is a particularly opportune time to review the market opportunities and future
growth prospects of this new emerging sector. The human microbiome-based drugs and diagnostics sector is nascent but a very rapidly developing field. While there are no marketed microbiome-based drugs on the market yet, the first generation of drugs and diagnostics could launch by 2018. The human microbiome-based drugs and diagnostics pipeline is strong with over 25 companies active in this space and over 50 programs in clinical/preclinical development. For companies seeking to exploit the growth in this industry, it is important to understand the competitive programs, and the potential for microbiome-based drugs and diagnostics to make meaningful decisions for future investments in this field.

Intended Audience
We have compiled a study of microbiome-based drugs and diagnostics that will be important in key enduser segments. We analyze the microbiome-based drug market by indication (e.g., cancer, gastrointestinal diseases, metabolic disorders etc.), by type of product (e.g., live bacteria, engineered bacteria, bacterial mixtures etc.), and by region (i.e., the U.S. and the rest of the world, which includes Europe, China, Japan and other countries). We examine the microbiome's scientific basis in various diseases, profile the microbiome products under development, and review intellectual property, corporate alliances and investments. We provide a holistic review of market potential and product sales forecasts by disease segment, by product and by region for the time period of 2017 to 2024.
This study will be of particular interest to companies in the following industries: pharmaceuticals, biotechnology, diagnostics companies, and life sciences venture capital and consulting firms.

Scope of Report
The scope of the study includes the major microbiome-based drugs and diagnostics that are likely to be commercialized within the next eight years. Each product within each market is analyzed to determine its market status, market potential during the time period of 2018 to 2024. Microbiome intellectual
property, investments and collaborations are discussed. Influencing factors, industry structure, challenges facing the industry and patent status are discussed.
BCC Research examines companies in the industry, corporate alliances and assay consumption by indication. We profile 25+ companies participating in this rapidly developing and evolving sector.

Information Sources
Both primary and secondary

Information Sources were used in preparing this study. BCC Research interviewed life science companies and research institutions to obtain data for this study. Included were diagnostics, drug firms and leading research institutions. In addition, we compiled data from secondary sources, including industry, trade and government organizations.

Methodology
BCC Research presents an analysis of each of the key market segments that will be commercially important during the 2017–2024 period: microbiome-based drugs for gastrointestinal disorders (ulcerative colitis, Crohn's disease, Clostridium difficle infection, lactose intolerance, celiac disease, hepatic encephalopathy and non-alcoholic steatohepatitis), cancer, bacterial infections (recurrent bacterial vaginosis and urinary tract infection, dental caries), orphan diseases (urea cycle disorders, phenylketonuria) and metabolic diseases (type 2 diabetes, obesity). We also conducted an analysis of microbiome-based diagnostics in various areas of disease. We used a bottom-up approach to estimate the market size for microbiome-based drugs and diagnostics. First, we forecast the patient epidemiology for each of the target disease based on the historical epidemiology growth rates.

Second, we estimate patient shares for various microbiome-based drugs. This was based on factors such as the order-of-entry and clinical potential of each of the drugs based on our discussions with microbiome experts. Using these estimates of the patient shares and segment patient volumes, we calculated the patient volumes for the microbiome-based drugs in each of the disease areas. Third, using current price of treatment for existing drugs in each of the market
segments as a benchmark, we estimated the cost of therapy for microbiome-based drugs. Finally, we used our estimates of cost of therapy to arrive at the forecast revenues for microbiome-based drugs. For each market segment, we provide a patient shares, patient volumes and sales revenue forecast for
microbiome-based drugs from 2017 through 2024 by indication for the U.S. and the rest of the world, which includes the E.U.-5 countries (Germany, Italy, U.K., France and Spain), China, Japan and other countries.

Geographic Breakdown
In this report, the geographic regions considered for market analysis include, and only include:
North America
• United States
• Mexico
• Canada
Europe
• France
• Germany
• Italy
Asia
• China
• India

Download the full report: https://www.reportbuyer.com/product/4923591/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com